ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu CAPVAXIVE®:MSD Merck Sharp & Dohme AG
Vollst. FachinformationDDDDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 

Stand der Information

Juni 2025
V116-I-OMA-RCN000026079-RCN000027402-CH
Revisions-Historie
2024-09-06-Advisory 01 received; 08.10.2024 Advisory 02 to add P008 received; 31.10.2024 submitted to SHI; LoQ received 04.02.2025; Advisory 03 received 07.03.2025; RtQ submitted 21.03.2025;PD received June 13 2025; Advisory 04 received July 09; rPD submitted July 31; informal labelling comments received 12.09.2025; Advisory received 15.09.2025 (all changes accepted); approval received 23.09.2025;

2025 ©ywesee GmbH
Einstellungen | Hilfe | Anmeldung | Kontakt | Home